Movement Alert｜Twist Bioscience Corp Intraday Rise 5.55% in Regular Trading, analyst initiations and Lilly TuneLab collaboration remain in focus

Market Focus10-28

On October 28, Twist Bioscience Corp rose 5.55% in Regular Trading, trading at $168.845 per share, with turnover of $33.5802 million.

The move coincided with continued market focus on recent analyst coverage and the company’s previously disclosed collaboration with Eli Lilly’s TuneLab platform in antibody drug discovery.

Recent public disclosures show Jefferies initiated coverage with a Hold rating and a $150 price target, while UBS initiated with a Neutral rating and a $144 price target. Separately, Twist Bioscience Corp said in September that it would provide antibody characterization data services to Lilly TuneLab, an AI and machine learning drug discovery platform created by Eli Lilly, reinforcing investor attention on the company’s role in AI-enabled drug discovery workflows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment